1
|
Kalthan E, Gouandjika-Vasilache I, Mbailao R, Doté J, Kossone M, Gbangai M. [Discovery of Foci of Type-2 Poliovirus Derived from Oral Polio Vaccine in Central African Republic in 2019]. MEDECINE TROPICALE ET SANTE INTERNATIONALE 2021; 1:mtsibulletin.2021.114. [PMID: 35586583 PMCID: PMC9022749 DOI: 10.48327/mtsibulletin.2021.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 06/04/2021] [Indexed: 11/05/2022]
Abstract
Objective In 2019, the Central African Republic identified foci of circulating vaccine-derived poliovirus 2 (PVDV2c). The objective of this work is to describe the vaccination status of children paralyzed by PVDV2c and their contacts and to assess the circulation of this strain in these contacts. Patients and method The study population of this retrospective survey consists of children with acute flaccid paralysis (AFP) and their contacts. We included paralyzed children whose sequencing results showed the presence of PVDV2c. Results A total of 21 children paralyzed by PVDVc and 64 contacts were enrolled in the survey. Fourteen out of 21 children who are paralyzed (66%) received at least one dose of bivalent oral polio vaccine (OPV) compared to 36 out of 64 contacts (57%, non-significant difference). Of the vaccinated patients, 7 had received less than three doses. For the injectable polio vaccine (IPV), vaccination coverage for both patients and contacts was 33%.The proportion of children who received both doses of OPV and IPV was 33% among patients and 25% in contacts. Contacts with VDPV2 were vaccinated with OPV and IPV, respectively 55 and 27%. VDPV2 and Sabin 2 were also found in contact stools, 34% and 9% respectively. Conclusion The absence or inadequacy of IPV vaccination has a serious impact on children by the occurrence of virus derived from the vaccine responsible for life-old paralysis. Protecting children from poliomyelitis requires a combination of a good cold chain, multiple doses and adherence to the vaccine schedule.
Collapse
Affiliation(s)
- E. Kalthan
- Ministère de la santé et de la population, direction de la surveillance épidémiologique et de gestion d'urgence en santé publique, République centrafricaine,*
| | - I. Gouandjika-Vasilache
- Institut Pasteur de Bangui, laboratoire régional de référence OMS pour la poliomyélite en Afrique, République centrafricaine
| | - R. Mbailao
- Ministère de la santé et de la population, direction générale de l'épidémiologie et de lutte contre les maladies, République centrafricaine
| | - J.W. Doté
- Institut Pasteur de Bangui, laboratoire régional de référence OMS pour la poliomyélite en Afrique, République centrafricaine
| | - M.N. Kossone
- Ministère de la santé et de la population, district sanitaire de Bambari, République centrafricaine
| | - M. Gbangai
- Ministère de la santé et de la population, service de la vaccination, République centrafricaine
| |
Collapse
|
2
|
Tournier JN. [The eradication of infectious viral diseases endangered by advances in synthetic biology]. Med Sci (Paris) 2019; 35:181-186. [PMID: 30774089 DOI: 10.1051/medsci/2019005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The eradication of infectious diseases is one of the oldest dreams of mankind. It has been materialized only once in History with smallpox in 1980. Considerable efforts are being developed against poliomyelitis viruses since 1988, but the ultimate goal of eradication is not yet achieved. Paradoxically, while the objective of having eradicated these two viral diseases is approaching, synthetic biology multiplies the prowesses of virus "neosynthesis", imperiling at least virtually the durability of these advances. This article emphasizes the potential of a new biology on one side, and the difficult reality of the fight against infections on the other.
Collapse
Affiliation(s)
- Jean-Nicolas Tournier
- Institut de recherche biomédicale des armées, Unité Biothérapies anti-infectieuses et immunité, Département Microbiologie et maladies infectieuses, 1, place général Valérie André, 91220 Brétigny-sur-Orge, France - Institut Pasteur, unité génomique virale et vaccination, CNRS UMR-3569, 25, rue du Docteur Roux, 75015 Paris, France - École du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France
| |
Collapse
|
3
|
Lizasoain A, Burlandy FM, Victoria M, Tort LFL, da Silva EE, Colina R. An Environmental Surveillance in Uruguay Reveals the Presence of Highly Divergent Types of Human Enterovirus Species C and a High Frequency of Species A and B Types. FOOD AND ENVIRONMENTAL VIROLOGY 2018; 10:343-352. [PMID: 29907902 DOI: 10.1007/s12560-018-9351-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 06/12/2018] [Indexed: 06/08/2023]
Abstract
Information about Human Enterovirus circulation in Uruguay is scarce. The aim of this study was to generate the first description about their circulation in the country through the study of sewage samples collected before and after the switch from Oral Poliovirus Vaccine to Inactivated Poliovirus Vaccine. Viruses were concentrated by an adsorption-elution to a negatively charged membrane, and real-time quantitative PCR and qualitative PCR methods were used to detect, quantify, and characterize enteroviruses. Positive samples were inoculated in RD cells and two passages were performed. Additionally, RD+ samples were subsequently passed onto L20B cells. Human Enteroviruses were detected in 67.6% of the samples, with concentrations between 4.9 and 6.6 Log10 genomic copies per liter. 10% of positive samples replicated in RD cells, of which none in L20B cells. Molecular characterization of Human Enterovirus strains directly detected from sewage sample concentrates allowed the identification of highly divergent members of species C such as Enterovirus C99 and Coxsackievirus A13, as well as the frequent detection of species A and B members (particularly Coxsackievirus A16 and Echovirus 6, respectively). Other detected types were Coxsackievirus A2, A22, B1, B5, Echovirus 5, and 9. The characterization of viruses isolated in cell culture revealed the presence of Echovirus 6 and Coxsackievirus B3. Despite the absence of poliovirus, a wide circulation of different enterovirus types was evidenced in Uruguayan sewage samples, highlighting that the local populations are exposed to different kinds of diseases originated by several human enterovirus.
Collapse
Affiliation(s)
- Andrés Lizasoain
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Sede Salto, Universidad de la República, Gral. Rivera 1350, 50000, Salto, Uruguay
| | - Fernanda M Burlandy
- Laboratório de Enterovírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Avda. Brasil 4365, Rio de Janeiro, 21040-360, Brazil
| | - Matías Victoria
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Sede Salto, Universidad de la República, Gral. Rivera 1350, 50000, Salto, Uruguay
| | - Luis F López Tort
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Sede Salto, Universidad de la República, Gral. Rivera 1350, 50000, Salto, Uruguay
| | - Edson E da Silva
- Laboratório de Enterovírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Avda. Brasil 4365, Rio de Janeiro, 21040-360, Brazil
| | - Rodney Colina
- Laboratorio de Virología Molecular, CENUR Litoral Norte, Sede Salto, Universidad de la República, Gral. Rivera 1350, 50000, Salto, Uruguay.
| |
Collapse
|
4
|
Londono-Renteria B, Troupin A, Colpitts TM. Arbovirosis and potential transmission blocking vaccines. Parasit Vectors 2016; 9:516. [PMID: 27664127 PMCID: PMC5035468 DOI: 10.1186/s13071-016-1802-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 09/14/2016] [Indexed: 12/21/2022] Open
Abstract
Infectious diseases caused by arboviruses (viruses transmitted by arthropods) are undergoing unprecedented epidemic activity and geographic expansion. With the recent introduction of West Nile virus (1999), chikungunya virus (2013) and Zika virus (2015) to the Americas, stopping or even preventing the expansion of viruses into susceptible populations is an increasing concern. With a few exceptions, available vaccines protecting against arboviral infections are nonexistent and current disease prevention relies on vector control interventions. However, due to the emergence of and rapidly spreading insecticide resistance, different disease control methods are needed. A feasible method of reducing emerging tropical diseases is the implementation of vaccines that prevent or decrease viral infection in the vector. These vaccines are designated ‘transmission blocking vaccines’, or TBVs. Here, we summarize previous TBV work, discuss current research on arboviral TBVs and present several promising TBV candidates.
Collapse
Affiliation(s)
- Berlin Londono-Renteria
- Department of Pathology, Microbiology and Immunology, University of South Carolina, Columbia, South Carolina, USA.
| | - Andrea Troupin
- Department of Pathology, Microbiology and Immunology, University of South Carolina, Columbia, South Carolina, USA
| | - Tonya M Colpitts
- Department of Pathology, Microbiology and Immunology, University of South Carolina, Columbia, South Carolina, USA
| |
Collapse
|
6
|
Simonyan V, Chumakov K, Dingerdissen H, Faison W, Goldweber S, Golikov A, Gulzar N, Karagiannis K, Vinh Nguyen Lam P, Maudru T, Muravitskaja O, Osipova E, Pan Y, Pschenichnov A, Rostovtsev A, Santana-Quintero L, Smith K, Thompson EE, Tkachenko V, Torcivia-Rodriguez J, Voskanian A, Wan Q, Wang J, Wu TJ, Wilson C, Mazumder R. High-performance integrated virtual environment (HIVE): a robust infrastructure for next-generation sequence data analysis. DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION 2016; 2016:baw022. [PMID: 26989153 PMCID: PMC4795927 DOI: 10.1093/database/baw022] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 02/09/2016] [Indexed: 02/03/2023]
Abstract
The High-performance Integrated Virtual Environment (HIVE) is a distributed storage and compute environment designed primarily to handle next-generation sequencing (NGS) data. This multicomponent cloud infrastructure provides secure web access for authorized users to deposit, retrieve, annotate and compute on NGS data, and to analyse the outcomes using web interface visual environments appropriately built in collaboration with research and regulatory scientists and other end users. Unlike many massively parallel computing environments, HIVE uses a cloud control server which virtualizes services, not processes. It is both very robust and flexible due to the abstraction layer introduced between computational requests and operating system processes. The novel paradigm of moving computations to the data, instead of moving data to computational nodes, has proven to be significantly less taxing for both hardware and network infrastructure. The honeycomb data model developed for HIVE integrates metadata into an object-oriented model. Its distinction from other object-oriented databases is in the additional implementation of a unified application program interface to search, view and manipulate data of all types. This model simplifies the introduction of new data types, thereby minimizing the need for database restructuring and streamlining the development of new integrated information systems. The honeycomb model employs a highly secure hierarchical access control and permission system, allowing determination of data access privileges in a finely granular manner without flooding the security subsystem with a multiplicity of rules. HIVE infrastructure will allow engineers and scientists to perform NGS analysis in a manner that is both efficient and secure. HIVE is actively supported in public and private domains, and project collaborations are welcomed. Database URL: https://hive.biochemistry.gwu.edu
Collapse
Affiliation(s)
- Vahan Simonyan
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Konstantin Chumakov
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Hayley Dingerdissen
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - William Faison
- Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Scott Goldweber
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Anton Golikov
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Naila Gulzar
- Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Konstantinos Karagiannis
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Phuc Vinh Nguyen Lam
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Thomas Maudru
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Olesja Muravitskaja
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Ekaterina Osipova
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Yang Pan
- Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Alexey Pschenichnov
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Alexandre Rostovtsev
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Luis Santana-Quintero
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Krista Smith
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Elaine E Thompson
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Valery Tkachenko
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - John Torcivia-Rodriguez
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Alin Voskanian
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Quan Wan
- Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Jing Wang
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Tsung-Jung Wu
- Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| | - Carolyn Wilson
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Raja Mazumder
- Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037, USA
| |
Collapse
|